A Potent Anti-HB-EGF Monoclonal Antibody Inhibits Cancer Cell Proliferation and Multiple Angiogenic Activities of HB-EGF

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Sato, Shuji ^a,b   Drake, Andrew W ^a   Tsuji, Isamu ^b   Fan, Jinhong ^a  

^a Takeda San Francisco Inc   (United States)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMPHIREGULIN; BEVACIZUMAB; CETUXIMAB; DIPHTHERIA TOXOID CRM197; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPITOPE; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY Y142; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; Y 142;

AMINO ACID SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CROSS REACTION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INHIBITION KINETICS; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RAT; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CROSS REACTIONS; EPITOPES; FIBROBLASTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SUBSTRATE SPECIFICITY;

RODENTIA;

EID: 84871304073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051964     Document Type: Article

References (59)

1. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M, (1991) A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939.
2. Elenius K, Paul S, Allison G, Sun J, Klagsbrun M, (1997) Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 16: 1268-1278.
3. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M, (1992) Structure of heparin-binding EGF-like growth factor. Multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem 267: 6205-6212.
4. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, et al. (1995) The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol 128: 929-938.
5. Shiomi T, Lemaître V, D'Armiento J, Okada Y, (2010) Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol Int 60: 477-496.
6. Goishi K, Higashiyama S, Klagsbrun M, Nakano N, Umata T, et al. (1995) Phorbol ester induces the rapid processing of cell surface heparin-binding EGF-like growth factor: conversion from juxtacrine to paracrine growth factor activity. Mol Biol Cell 6: 967-980.
7. Takenobu H, Yamazaki A, Hirata M, Umata T, Mekada E, (2003) The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades. J Biol Chem 278: 17255-17262.
8. Nanba D, Mammoto A, Hashimoto K, Higashiyama S, (2003) Proteolytic release of the carboxy-terminal fragment of proHB-EGF causes nuclear export of PLZF. J Cell Biol 163: 489-502.
9. Kinugasa Y, Hieda M, Hori M, Higashiyama S, (2007) The carboxyl-terminal fragment of pro-HB-EGF reverses Bcl6-mediated gene repression. J Biol Chem 282: 14797-14806.
10. Iwamoto R, Yamazaki S, Asakura M, Takashima S, Hasuwa H, et al. (2003) Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function. Proc Natl Acad Sci U S A 100: 3221-3226.
11. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, et al. (2003) Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 22: 2704-2716.
12. Mine N, Iwamoto R, Mekada E, (2005) HB-EGF promotes epithelial cell migration in eyelid development. Development 132: 4317-4326.
13. Shirakata Y, Kimura R, Nanba D, Iwamoto R, Tokumaru S, et al. (2005) Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing. J Cell Sci 118: 2363-2370.
14. Das SK, Wang XN, Paria BC, Damm D, Abraham JA, et al. (1994) Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation. Development 120: 1071-1083.
15. Raab G, Kover K, Paria BC, Dey SK, Ezzell RM, et al. (1996) Mouse preimplantation blastocysts adhere to cells expressing the transmembrane form of heparin-binding EGF-like growth factor. Development 122: 637-645.
16. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40.
17. Powell PP, Klagsbrun M, Abraham JA, Jones RC, (1993) Eosinophils expressing heparin-binding EGF-like growth factor mRNA localize around lung microvessels in pulmonary hypertension. Am J Pathol 143: 784-793.
18. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, et al. (1995) Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest 95: 404-411.
19. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, et al. (1995) T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A 92: 6547-6551.
20. Fu S, Bottoli I, Goller M, Vogt PK, (1999) Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc Natl Acad Sci U S A 96: 5716-5721.
21. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, et al. (1994) Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202: 1705-1709.
22. Naef M, Yokoyama M, Friess H, Büchler MW, Korc M, (1996) Co-expression of heparin-binding EGF-like growth factor and related peptides in human gastric carcinoma. Int J Cancer 66: 315-321.
23. Mishima K, Higashiyama S, Asai A, Yamaoka K, Nagashima Y, et al. (1998) Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas. Acta Neuropathol 96: 322-328.
24. Thøgersen VB, Sørensen BS, Poulsen SS, Ørntoft TF, Wolf H, et al. (2001) A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 61: 6227-6233.
25. Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, et al. (2004) Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727.
26. Tanaka Y, Miyamoto S, Suzuki SO, Oki E, Yagi H, et al. (2005) Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 11: 4783-4792.
27. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P, (2009) A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res 15: 5191-5198.
28. Tsujioka H, Fukami T, Yotsumoto F, Ueda T, Hikita S, et al. (2011) A possible clinical adaptation of CRM197 in combination with conventional chemotherapeutic agents for ovarian cancer. Anticancer Res 31: 2461-2465.
29. Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, et al. (2011) A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells. Clin Cancer Res 17: 6733-6741.
30. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH, (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49: 493-507.
31. Buzzi S, Rubboli D, Buzzi G, Buzzi AM, Morisi C, et al. (2004) CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 53: 1041-1048.
32. Khong TF, Fraser S, Katerelos M, Paizis K, Hill PA, et al. (2000) Inhibition of heparin-binding epidermal growth factor-like growth factor increases albuminuria in puromycin aminonucleoside nephrosis. Kidney Int 58: 1098-1107.
33. Hamaoka M, Chinen I, Murata T, Takashima S, Iwamoto R, et al. (2010) Anti-human HB-EGF monoclonal antibodies inhibiting ectodomain shedding of HB-EGF and diphtheria toxin binding. J Biochem 148: 55-69.
34. Tsuji I, Sato S, Otake K, Watanabe T, Kamada H, et al. (2012) Characterization of a variety of neutralizing anti-heparin-binding epidermal growth factor-like growth factor monoclonal antibodies by different immunization methods. mAbs [Epub ahead of print].
35. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, et al. (2005) Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 7: 426-431.
36. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E, (1995) Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270: 1015-1019.
37. Yu L, Liang XH, Ferrara N, (2011) Comparing protein VEGF inhibitors: In vitro biological studies. Biochem Biophys Res Commun 408: 276-281.
38. Darling RJ, Brault PA, (2004) Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev Technol 2: 647-657.
39. Blake RCII, Delehanty JB, Khosraviani M, Yu H, Jones RM, et al. (2003) Allosteric binding properties of a monoclonal antibody and its Fab fragment. Biochemistry 42: 497-508.
40. Abramovitch R, Neeman M, Reich R, Stein I, Keshet E, et al. (1998) Intercellular communication between vascular smooth muscle and endothelial cells mediated by heparin-binding epidermal growth factor-like growth factor and vascular endothelial growth factor. FEBS Lett 425: 441-447.
41. Ushiro S, Ono M, Izumi H, Kohno K, Taniguchi N, et al. (1996) Heparin-binding epidermal growth factor-like growth factor: p91 activation induction of plasminogen activator/inhibitor, and tubular morphogenesis in human microvascular endothelial cells. Jpn J Cancer Res 87: 68-77.
42. Hoskins JT, Zhou Z, Harding PA, (2008) The significance of disulfide bonding in biological activity of HB-EGF, a mutagenesis approach. Biochem Biophys Res Commun 375: 506-511.
43. Jin P, Zhang J, Beryt M, Turin L, Brdlik C, et al. (2009) Rational optimization of a bispecific ligand trap targeting EGF receptor family ligands. Mol Med 15: 11-20.
44. Brooke JS, Cha JH, Eidels L, (1998) Diphtheria toxin:receptor interaction: association, dissociation, and effect of pH. Biochem Biophys Res Commun 248: 297-302.
45. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J, (1995) Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1: 1311-1318.
46. Hommel U, Harvey TS, Driscoll PC, Campbell ID, (1992) Human epidermal growth factor. High resolution solution structure and comparison with human transforming growth factor alpha. J Mol Biol 227: 271-282.
47. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110: 775-787.
48. Engler DA, Campion SR, Hauser MR, Cook JS, Niyogi SK, (1992) Critical functional requirement for the guanidinium group of the arginine 41 side chain of human epidermal growth factor as revealed by mutagenic inactivation and chemical reactivation. J Biol Chem 267: 2274-2281.
49. Koide H, Muto Y, Kasai H, Kohri K, Hoshi K, et al. (1992) A site-directed mutagenesis study on the role of isoleucine-23 of human epidermal growth factor in the receptor binding. Biochim Biophys Acta 1120: 257-261.
50. Tadaki DK, Niyogi SK, (1993) The functional importance of hydrophobicity of the tyrosine at position 13 of human epidermal growth factor in receptor binding. J Biol Chem 268: 10114-10119.
51. Jones JT, Ballinger MD, Pisacane PI, Lofgren JA, Fitzpatrick VD, et al. (1998) Binding interaction of the heregulinbeta egf domain with ErbB3 and ErbB4 receptors assessed by alanine scanning mutagenesis. J Biol Chem 273: 11667-11674.
52. Cook PW, Mattox PA, Keeble WW, Pittelkow MR, Plowman GD, et al. (1991) A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. Mol Cell Biol 11: 2547-2557.
53. Inui S, Higashiyama S, Hashimoto K, Higashiyama M, Yoshikawa K, et al. (1997) Possible role of coexpression of CD9 with membrane-anchored heparin-binding EGF-like growth factor and amphiregulin in cultured human keratinocyte growth. J Cell Physiol 171: 291-298.
54. Nakagawa M, Nabeshima K, Asano S, Hamasaki M, Uesugi N, et al. (2009) Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci 100: 654-662.
55. McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ, (2010) The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 122: 105-110.
56. Ruck A, Paulie S, (1998) EGF, TGF alpha, AR and HB-EGF are autocrine growth factors for human bladder carcinoma cell lines. Anticancer Res 18: 1447-1452.
57. O-Charoenrat P, Rhys-Evans P, Eccles S, (2000) Expression and regulation of c-ERBB ligands in human head and neck squamous carcinoma cells. Int J Cancer 88: 759-765.
58. Tørring N, Jørgensen PE, Sørensen BS, Nexø E, (2000) Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines. Anticancer Res 20: 91-95.
59. Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, et al. (2008) Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun 365: 555-561.